Compare OSK & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSK | AXSM |
|---|---|---|
| Founded | 1917 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 8.6B |
| IPO Year | 2009 | 2015 |
| Metric | OSK | AXSM |
|---|---|---|
| Price | $152.90 | $183.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 17 |
| Target Price | $166.79 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 533.7K | 503.9K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $7,705,500,000.00 | N/A |
| Revenue This Year | $5.94 | $57.24 |
| Revenue Next Year | $7.19 | $55.88 |
| P/E Ratio | $129.91 | ★ N/A |
| Revenue Growth | ★ 12.83 | N/A |
| 52 Week Low | $82.14 | $96.09 |
| 52 Week High | $180.49 | $191.50 |
| Indicator | OSK | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 54.21 | 60.51 |
| Support Level | $137.24 | $178.00 |
| Resistance Level | $158.57 | $184.40 |
| Average True Range (ATR) | 5.57 | 5.55 |
| MACD | 0.77 | 0.93 |
| Stochastic Oscillator | 74.66 | 72.42 |
Oshkosh is a leading maker of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, including postal, firefighting, refuse/recycling collection, aviation, and construction. It is typically the market share leader or No. 2 player in North America, or even the global leader in the case of its JLG aerial work platform business. The transport segment is a leading provider of light trucks to the military and vehicles to the Postal Service. The vocational segment, featuring brands such as Pierce, AeroTech, and Volterra, offers purpose-built vehicles and equipment to municipalities. The company reports three segments—Access equipment (45% of revenue), Vocational (35%), and Transport (20%) on 2025 revenue of $10.4 billion.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.